ArticleFrontiers in oncology2026
Primary large cell neuroendocrine carcinoma of the breast with metastasis in the lymph nodes: a case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary large cell neuroendocrine carcinoma (LCNEC) of the breast is an extremely rare and diagnostically challenging subtype. A 47-year-old female was admitted to Weifang People's Hospital (Weifang, China) with a left breast mass that was incidentally detected. The tumor demonstrated a unique triple-negative immunophenotype and presented significant diagnostic pitfalls, mimicking conventional triple-negative breast cancer (TNBC). Modified radical mastectomy was performed after neoadjuvant chemotherapy. Based on the clinical, imaging and pathological findings, she was diagnosed with primary LCNEC of the breast with lymph node metastasis. Accurate distinction from TNBC with focal neuroendocrine differentiation and metastatic neuroendocrine carcinoma is critical. Short-term follow-up (9 months) suggests favorable disease control, but long-term efficacy and prognosis remain undetermined due to limited follow-up. This case highlights the clinical significance of avoiding misdiagnosis, with immunohistochemistry providing key diagnostic clues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.